Mexico Nuclear Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mexico nuclear imaging market size is expected to grow from USD 297.1 million in 2025 to USD 313.32 million in 2026 and is forecast to reach USD 408.7 million by 2031 at 5.46% CAGR over 2026-2031. This report is Segmented by Product (Equipment: PET/CT Scanners, SPECT/CT Scanners, PET/MRI Scanners; Radioisotopes: SPECT and PET Radioisotopes), Application (SPECT and PET Applications), End User (Hospitals, Diagnostic Imaging Centres, Academic & Research Institutes). The Market Forecasts are Provided in Terms of Value (USD).

Mexico Nuclear Imaging Market Trends and Insights

Rising Cancer & Cardiovascular Incidence

Non-communicable disease prevalence continues to climb in Mexico, driving demand for myocardial perfusion imaging and FDG-PET scans. Cancer incidence is highest in Mexico City, Guadalajara, and Monterrey, and an aging population keeps procedure pipelines full for staging and response monitoring. Expanded IMSS-Bienestar coverage broadens access to molecular imaging among previously underserved households, lifting scan volumes at both public and private facilities. The IAEA ARCAL 2030 plan lists Mexico among nations in Latin America that must reinforce nuclear medicine capacity to meet oncology and cardiology workloads. The predictable patient base encourages capital allocation for hybrid scanners and in-house radiopharmacies.

Public-Sector Imaging Capex (INSABI, IMSS)

The federal consolidated procurement platform covering 2025-2026 earmarks multiyear budgets for high-tech equipment, radioisotopes, and service contracts across IMSS-Bienestar and ISSSTE hospitals. Centralized purchasing through state manufacturer Birmex aggregates volumes, improving supplier terms and shortening tender cycles. Public bids stipulate hybrid modality preferences, pushing vendors to package scanners, software, maintenance, and workforce training. Regional medical centers in secondary cities gain stable funding streams that justify nuclear medicine suite build-outs. Early purchase orders released in 2025 feature SPECT/CT systems and dedicated PET hot cells, signaling near-term volume for both equipment and consumables.

High Equipment & Maintenance Costs

Capital intensity requirements for nuclear imaging equipment create significant barriers to market entry, particularly affecting smaller healthcare facilities and limiting geographic expansion beyond major metropolitan areas. PET/CT systems require investments exceeding USD 2 million, while ongoing maintenance contracts and isotope procurement create substantial operational expenses that strain facility budgets. The technical complexity of nuclear imaging systems necessitates specialized service agreements with original equipment manufacturers, often requiring international technician support that increases maintenance costs. Smaller diagnostic centers struggle to achieve sufficient patient volumes to justify hybrid system investments, creating market concentration among larger facilities with adequate financial resources. Currency fluctuations between the Mexican peso (MXN) and US dollar (USD) affect equipment procurement costs, as most nuclear imaging systems are imported from international manufacturers. Limited availability of local technical expertise increases dependence on expensive international service contracts and extends system downtime during maintenance procedures.

Other drivers and restraints analyzed in the detailed report include:

• Hybrid SPECT/CT & PET/CT Upgrades
• Private Nuclear-Pharmacy Build-out
• Mo-99 Supply Delays at Mexican Customs

Segment Analysis

Radioisotopes commanded 61.58% of the Mexico nuclear imaging market share in 2025. The Mexico nuclear imaging market size for radioisotopes is projected to rise at a 5.58% CAGR to 2031 as Technetium-99m continues to anchor SPECT demand. Consumables spending is recurrent, generating predictable cash flow for radiopharmaceutical vendors and prompting new entrants to establish GMP-grade production lines. Curium Pharma’s March 2025 acquisition of Monrol expanded Latin American Lutetium-177 output capacity and positions the firm to supply therapeutic isotopes for prostate cancer programs. PET tracers, led by Fluorine-18, log the fastest volume growth owing to oncology indications, and wider distribution of cyclotrons in tertiary cities further supports adoption. Capital equipment, while representing only 38.42% of 2025 value, exerts pivotal influence on long-term modality mix. Replacement cycles of 10-15 years shape tender calendars, allowing OEMs to introduce novel detector technologies and dose-reduction software that reinforce the hybrid migration trend.

Equipment procurement remains concentrated in high-acuity metropolitan hospitals that can shoulder million-dollar outlays and maintain qualified staff. Smaller facilities gravitate toward refurbished scanners or service subscriptions that bundle uptime guarantees and per-scan pricing. Currency risk persists because nearly all hardware is imported. Vendors that provide peso-denominated leasing, remote diagnostics, and on-site training win share, especially in diagnostic center chains expanding outside the capital. The expanding PET tracer portfolio, including Ga-68 and Zr-89, is expected to boost theranostics programs and tilt purchasing toward systems with time-of-flight and extended field-of-view capabilities.

Complete Report Scope:

• By Product
  • Equipment
    • PET/CT Scanners
    • SPECT/CT Scanners
    • PET/MRI Scanners
  • Radioisotopes
    • SPECT Radioisotopes
      • Technetium-99m (Tc-99m)
      • Thallium-201 (Tl-201)
      • Gallium-67 (Ga-67)
      • Iodine-123 (I-123)
      • Other SPECT Isotopes
    • PET Radioisotopes
      • Fluorine-18 (F-18)
      • Rubidium-82 (Rb-82)
      • Other PET Isotopes
• By Application
  • SPECT Applications
    • Cardiology
    • Neurology
    • Thyroid
    • Other SPECT Applications
  • PET Applications
    • Oncology
    • Cardiology
    • Neurology
    • Other PET Applications
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Academic & Research Institutes

List of Companies Covered in this Report:

• GE Healthcare
• Siemens Healthineers
• Koninklijke Philips
• Canon
• Curium Pharma
• Canon
• Bracco
• FUJIFILM
• Mediso
• Bracco
• Novartis
• Bayer
• United Imaging Healthcare
• Spectrum Dynamics Medical
• Telix Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support